Long-term Study of Epiduo in Patients With Moderate to Severe Acne
Launched by GALDERMA LABORATORIUM GMBH · Jun 12, 2012
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
This observational study is designed to assess the long-term efficacy and safety of Epiduo under daily clinical practice conditions. The study includes patients of all ages with moderate to severe inflammatory acne, taking Epiduo alone or in combination with other drugs. In addition, the effect of Epiduo alone or in combination with other drugs on quality of life and patient adherence will be assessed under marketed conditions.
The observational study is designed as a multicentre study, covering all parts of Germany. Participating investigators are dermatologists with an adequate patient p...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient has been diagnosed with moderate to severe inflammatory acne (Leeds Grade 4-12)
- • Topical therapy of acne with Epiduo is indicated, the decision about treating the patient with Epiduo has been made independently from this study
- Exclusion Criteria:
- • Use of Epiduo within 3 months prior to inclusion
- • Pregnancy or breastfeeding
- • Acne inversa
- • Acne with preferential manifestation of microcysts, macrocysts and macrocomedones
- • Hypersensitivity to the drug or any of its ingredients
- • If applicable, other restrictions outlined in the SPC of Epiduo
About Galderma Laboratorium Gmbh
Galderma Laboratorium GmbH is a leading global pharmaceutical company dedicated to advancing dermatological science and improving patient outcomes through innovative research and development. With a strong focus on medical and aesthetic dermatology, Galderma specializes in delivering high-quality products and solutions that address a wide range of skin conditions. Committed to scientific excellence and patient safety, the company collaborates with healthcare professionals and researchers worldwide to conduct clinical trials that underpin its robust portfolio of prescription and over-the-counter offerings. Galderma's mission is to enhance the quality of life for patients by providing effective and accessible dermatological therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Harald PM Gollnick, Prof. Dr.
Principal Investigator
Universitätsklinikum Magdeburg A.ö.R. Klinik für Dermatologie und Venerologie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials